Welcome to the Office of Cancer Survivorship Program, DCCPS
The NCI Office of Cancer Survivorship (OCS) works to enhance the quality and length of survival of all persons diagnosed with cancer and to prevent, minimize, or manage adverse effects of cancer and its treatment.
Many people being treated for cancer and longer-term cancer survivors report regularly drinking alcohol—some heavily and often, a new study shows. Read more in this new NCI Cancer Currents Blog.
October 2023 – Register now for this upcoming OCS Director’s Series webinar. On October 17, 2023, from 2-3 p.m. ET, Dr. Angela E. Usher and Dr. Brenda Adjei will present Understanding and Addressing Housing Instability for Cancer Survivors.
November 2023 – On November 7, 2023, from 2-3 p.m. ET, NIH Tribal Health Research Office Director Dr. Karina L. Walters will present Beyond Survivance: Thrivance Among American Indian and Alaska Native Cancer Survivors. Register now for this upcoming OCS Director’s Series webinar.
November 2023 – Join the NCI Office of Cancer Survivorship for this upcoming OCS New Investigators Series webinar. On November 14, 2023, from 2-3 p.m. ET, Dr. Anne C. Kirchhoff will present Navigating and Surviving the Twists and Turns of Survivorship Funding and Research. Register now.
About The Office of Cancer Survivorship
An individual is considered a cancer survivor from the time of diagnosis, through the balance of life. There are many types of survivors, including those living with cancer and those free of cancer. This term is meant to capture a population of those with a history of cancer rather than to provide a label that may or may not resonate with individuals.
OCS works to promote a better understanding of unique needs of the growing population of cancer survivors, and to enhance our ability to address them.
Featured Graph and Statistic
Researchers at the National Cancer Institute have estimated that 623,405 people in the United States were living with metastatic breast, prostate, lung, colorectal, or bladder cancer or metastatic melanoma as of 2018, and that number is expected to increase to 693,452 by the year 2025.